🚀 VC round data is live in beta, check it out!
Spyre Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Spyre Therapeutics and similar public comparables like Edgewise Therapeutics, Tarsus Pharmaceuticals, Jilin Aodong, United Laboratories International and more.
Spyre Therapeutics Overview
About Spyre Therapeutics
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Founded
2013
HQ
Employees
102
Website
Sectors
Financials (LTM)
EV
$3B
Spyre Therapeutics Financials
Spyre Therapeutics reported last 12-month revenue of — and negative EBITDA of ($218M).
In the same LTM period, Spyre Therapeutics generated — in gross profit, ($218M) in EBITDA losses, and had net loss of ($174M).
Revenue (LTM)
Spyre Therapeutics P&L
In the most recent fiscal year, Spyre Therapeutics reported revenue of — and EBITDA of ($210M).
Spyre Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($218M) | XXX | ($210M) | XXX | XXX | XXX |
| Net Profit | ($174M) | XXX | ($155M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Spyre Therapeutics Stock Performance
Spyre Therapeutics has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Spyre Therapeutics' stock price is $41.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $-1.98 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSpyre Therapeutics Valuation Multiples
Spyre Therapeutics trades at (12.0x) EV/EBITDA.
EV / Revenue (LTM)
Spyre Therapeutics Financial Valuation Multiples
As of March 21, 2026, Spyre Therapeutics has market cap of $3B and EV of $3B.
Equity research analysts estimate Spyre Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Spyre Therapeutics has a P/E ratio of (18.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/EBITDA | (12.0x) | XXX | (12.5x) | XXX | XXX | XXX |
| EV/EBIT | (11.8x) | XXX | (12.5x) | XXX | XXX | XXX |
| P/E | (18.6x) | XXX | (20.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (15.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Spyre Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Spyre Therapeutics Margins & Growth Rates
Spyre Therapeutics' revenue in the last fiscal year declined by (100%).
Spyre Therapeutics' revenue per employee in the last FY averaged $0.0M.
Spyre Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 18% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Spyre Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Edgewise Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tarsus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Jilin Aodong | XXX | XXX | XXX | XXX | XXX | XXX |
| United Laboratories International | XXX | XXX | XXX | XXX | XXX | XXX |
| TransThera Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spyre Therapeutics M&A Activity
Spyre Therapeutics acquired XXX companies to date.
Last acquisition by Spyre Therapeutics was on XXXXXXXX, XXXXX. Spyre Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Spyre Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSpyre Therapeutics Investment Activity
Spyre Therapeutics invested in XXX companies to date.
Spyre Therapeutics made its latest investment on XXXXXXXX, XXXXX. Spyre Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Spyre Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Spyre Therapeutics
| When was Spyre Therapeutics founded? | Spyre Therapeutics was founded in 2013. |
| Where is Spyre Therapeutics headquartered? | Spyre Therapeutics is headquartered in United States. |
| How many employees does Spyre Therapeutics have? | As of today, Spyre Therapeutics has over 102 employees. |
| Who is the CEO of Spyre Therapeutics? | Spyre Therapeutics' CEO is Cameron Turtle. |
| Is Spyre Therapeutics publicly listed? | Yes, Spyre Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Spyre Therapeutics? | Spyre Therapeutics trades under SYRE ticker. |
| When did Spyre Therapeutics go public? | Spyre Therapeutics went public in 2016. |
| Who are competitors of Spyre Therapeutics? | Spyre Therapeutics main competitors are Edgewise Therapeutics, Tarsus Pharmaceuticals, Jilin Aodong, United Laboratories International. |
| What is the current market cap of Spyre Therapeutics? | Spyre Therapeutics' current market cap is $3B. |
| Is Spyre Therapeutics profitable? | No, Spyre Therapeutics is not profitable. |
| What is the current EBITDA of Spyre Therapeutics? | Spyre Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Spyre Therapeutics? | Current EBITDA multiple of Spyre Therapeutics is (12.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.